# US 12,213,989 B2 · Use of maribavir in treatment regimens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,213,989 B2
- Document ID: US12213989B2
- Status: Granted
- Kind: B2
- Application number: 18/646,035
- Filed: 2024-04-25
- Published: 2024-08-29
- Granted: 2025-02-04
- Earliest claimed: 2021-11-19
- Assignees: Takeda Pharmaceutical Company Limited
- Applicants: Takeda Pharmaceutical Company Limited
- Inventors: Heng Song; Kefeng Sun; Matthew Crouthamel; Grace Chen; Andy Z. X. Zhu; Ingrid Nicolle Michon; Howard James Burt; Zoe Elizabeth Barter; Sibylle Neuhoff
- Web page: https://patentgrep.com/patent/US12213989B2

## CPC

- A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom
- A61K 31/365: Lactones
- A61K 31/4166: having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 36/38: Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/22: for herpes viruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Characterization of drug-drug interaction properties and pharmacological properties of maribavir is useful to inform potential drug-drug interactions and dosing strategies when administering with co-medications.

## Claims

### Claim 1

A method of treating cytomegalovirus (CMV) infection in a patient suffering therefrom, the method comprising
administering maribavir in an amount of 1200 mg orally twice daily, wherein the patient is a transplant recipient concomitantly exposed to or receiving an anticonvulsant selected from phenytoin or phenobarbital,
wherein maribavir is administered prior to, concurrently with, or subsequently from the administration of the anticonvulsant.

### Claim 2 (depends on 1)

The method of claim 1, wherein the anticonvulsant is phenytoin.

### Claim 3 (depends on 1)

The method of claim 1, wherein the anticonvulsant is phenobarbital.

### Claim 4 (depends on 1)

The method of claim 1, wherein the patient is an adult or a child of 12 years of age or older, and wherein the patient weighs at least 35 kg.

### Claim 5 (depends on 1)

The method of claim 1, wherein the patient is refractory to treatment with one or more of ganciclovir, valganciclovir, cidofovir, or foscarnet.

### Claim 6 (depends on 1)

The method of claim 1, wherein the patient is a hematopoietic stem cell transplant recipient.

### Claim 7 (depends on 1)

The method of claim 1, wherein the patient is a solid organ transplant recipient.